News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
223 Results
Type
Article (6)
Press Release (217)
Section
Business (90)
Deals (9)
Drug Development (18)
FDA (2)
News (128)
Policy (18)
Tag
Alliances (11)
Approvals (2)
Clinical research (16)
Earnings (36)
Events (27)
FDA (2)
IPO (5)
Layoffs (1)
Legal (1)
Mergers & acquisitions (4)
NextGen Class of 2024 (1)
People (37)
Phase I (7)
Phase II (3)
Phase III (4)
Postmarket research (4)
Preclinical (1)
Regulatory (17)
Startups (4)
Date
Last 365 days (2)
2024 (2)
2022 (10)
2021 (4)
2020 (1)
2019 (4)
2018 (18)
2017 (47)
2016 (43)
2015 (52)
2014 (28)
2013 (6)
2012 (3)
2010 (1)
Location
Asia (4)
Europe (17)
223 Results for "egalet".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Adare Acquires Egalet’s Proprietary “ParvuletTM” Technology Platform
Adare Pharmaceuticals, Inc. announced that it has entered into an agreement with Egalet Corporation, to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property.
April 15, 2019
·
3 min read
Pharm Country
Egalet to Present at Upcoming Conferences
Egalet Corporation announced that members of the Egalet clinical and development teams will be presenting at two upcoming conferences.
March 21, 2018
·
2 min read
Deals
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019
Egalet Corporation announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019.
May 14, 2019
·
4 min read
Deals
Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences
Egalet Corporation reported financial results for the first quarter ended March 31, 2019 and announced it will change its name to Zyla Life Sciences in the coming weeks.
May 16, 2019
·
9 min read
Business
Egalet Reports Fourth Quarter and Full Year 2017 Financial Results
Egalet Corporation reported financial results for the fourth quarter and year ended December 31, 2017.
March 12, 2018
·
21 min read
Business
Egalet Announces Third Quarter 2017 Financial Results
Egalet today announced financial results for the third quarter ended September 30, 2017.
November 8, 2017
·
18 min read
Pharm Country
Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference
Egalet Corporation announced Bob Radie, president and chief executive officer, will present in panels at two upcoming conferences in June.
June 4, 2018
·
4 min read
Business
Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018
Egalet Corporation announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018.
July 25, 2018
·
5 min read
Pharm Country
Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray
Egalet Corporation announced that a large Southeast regional health plan has placed SPRIX (ketorolac tromethamine) Nasal Spray in a tier 3 covered position effective immediately.
May 29, 2018
·
10 min read
Drug Development
Egalet Announces Positive Top-Line Results From Phase III Safety Study Evaluating Safety of Egalet-002
Egalet-002 was generally well-tolerated and the incidence of adverse events reported was generally consistent with outcomes expected following treatment with an extended-release oxycodone formulation.
November 16, 2017
·
6 min read
1 of 23
Next
